Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Genomics Adds Kinase to Collaboration with Serono

NEW YORK, Nov. 19 (GenomeWeb News) - Cellular Genomics said today it has added an additional drug target to its kinase discovery collaboration with Serono.

 

Under the agreement, Cellular Genomics will use its Analog Sensitive Kinase Allele technology to produce modified kinases for Serono, and will use its P-inhibitor technology to study consequences of kinase inhibition in vivo and to map kinase signaling pathways for Serono.

 

The Brandord, Conn.-based chemical genomics company, first signed the agreement with Serono in October 2002, to apply its chemical genetics technologies to four kinase drug targets that Serono had selected. Cellular Genomics' ASKA   technology consists of   genetically modified kinases that act like normal kinases, but can be selectively and specifically inhibited with a small-molecule inhibitor the company has designed.

 

The parties did not disclose the financial terms of the agreement.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.